The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
